1.Alternative Name:4Ig-B7-H3,CD276
2.Target:B7-H3
3.Source:Human B7-H3 was expressed from HEK293 with human IgG1 FC at the C-terminal
4.Sequence:Met1-Thr461
5.Protein structure:Q5ZPR3hFC
6.Molecular Characterization:The protein has a calculated MW of 73kDa.The reducing (R) heterodimer protein migrates as 100-120 kDa due to glycosylation
7.Purity:SDS-PAGE>90%，SEC>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
Note:For research use only .


11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 90%.

12.SEC-HPLC

Determined by SEC-HPLC, the purity of the protein is greater than 95%.

13.ELISA

When Recombinant Human B7-H3(CD276) / hFC Protein is immobilized at 5μg/mL (100 μL/well), the concentration of Anti-Human CD276 (Enoblituzumab) that produces 50% of the optimal binding response is approximately 50 ng/ml.